“Latest Stem Cells News”

A breakthrough was achieved recently in the case of an 18 year old boy, a case of advanced stage of Aplastic anemia where stem cells of not one but three donors were used to treat him. This spectacular feat was achieved by the doctors at The Netaji Subhash Chandra Bose Cancer Research Institute (NSCBCRI) Kolkata.

18 year old Aman, student of class 12, fainted in school. He was diagnosed for Aplastic Anemia, a disorder where the bone marrow stops producing red blood cells and platelets. He was treated in many hospitals, but no amount of blood transfusions or ‘immuno-suppressant’ medication could help.

Dejected and depressed, Aman’s parents had almost lost their son when they happened to read a news report by chance. The doctors at NSCBCRI had successfully conducted an SCT to treat Aplastic anemia. . “I wanted to live on, and my parents saw a ray of hope, ”said Aman.
With recent advances in medicine the use of stem cells have been very effective in treating Diabetes milletus, Parkinson’s diseases, cancer, leukemia and Aplastic anemia .

They have been very effective in Bone marrow transplantation
Aman was rushed to Kolkata, but by then his condition had deteriorated. The doctors realized that only a multiple- unit SCT could save him. Overruling the risks they conducted the transplant which took three days.

With 50% chances of risk involved in a single unit SCT, the doctors had a bigger risk at hand, but a similar case conducted successfully in Seattle gave them the courage.
Today Aman Khandelwal is recouping. Thanks to the courage, confidence and competence of the doctors who treated upon him.

from http://www.beviga.com/1401/stem-cell-transplant-a-miracle/

Incoming search terms:

The California Institute for Regenerative Medicine (CIRM) and the Chinese Ministry of Science and Technology (MOST) have agreed to collaborate on stem cell research. The agreement will make it easier to form cross-border teams that are working in similar areas. If the teams’ funding requests are approved, the researchers in each country will be supported by their respective agency, CIRM or MOST. The formal announcement, made today, adds details to a story that ChinaBio® Today originally broke late last week (…)

“Our collaboration will benefit patients in our countries and patients around the globe,” said Wan Gang, Minister, MOST. “We should be aware that stem cell research will require a long-term effort and basic research to address unanswered questions. When we move to medical therapies, it must be with the highest standards.”

“One of CIRM’s primary goals is to accelerate the field of stem cell research as a whole, and in some instances we can do this more effectively through collaborations that involve the best scientific endeavors, regardless of geography,” said CIRM’s Trounson. “China is developing a major national program in stem cells and regenerative medicine that can be effectively matched with California’s excellence in stem cell science that is rapidly evolving in academic and biotechnology settings. I would expect major developments for patients to occur through this new partnership.”

CIRM was established in 2005 by a California ballot initiative that provided $3 billion in funding for stem cell research in California institutions. The money is to be allocated over 10 years. So far, CIRM has approved 307 research and facility grants for a total of more than $781 million. CIRM claims to be the largest source of funding for human embryonic stem cell research in the world.

from http://www.istockanalyst.com/article/viewarticle/articleid/3562981

Incoming search terms:

Several cell-based therapy approaches could provide new treatments for patients with Alport syndrome, reports an upcoming paper in the Journal of the American Society of Nephrology.

“Our study opens up many considerations of how new therapies related to the use of stem cells can be devised for our kidney patients with chronic disease,” comments Raghu Kalluri, MD, PhD (Harvard Medical School, Boston, MA) (…)

The experiments provide evidence that stem cell treatments could repair the kidney defects associated with Alport syndrome. “We found that stem cells derived from adult bone marrow are equally useful as embryonic stem cells,” says Kalluri. “This will make it easier to translate these scientific discoveries to a treatment protocol for patients with Alport syndrome.” (…)

from http://www.sciencedaily.com/releases/2009/10/091015171451.htm

Incoming search terms:

MIAMI, Fla. (Ivanhoe Newswire) — Some are calling it the next big frontier in cardiac treatment — injecting stem cells to regenerate the heart. But the experimental procedure means major surgery. Doctors are opening the door for heart patients who want to test the benefits of stem cells — without an operation.

One heart attack behind him, Max Eaton is now struggling with heart failure. He’s hoping stem cells are the answer to heal his ailing heart. “I happened to run into this article, which was the second or third time I heard about this stem cell research, and decided nothing ventured, nothing gained,” Eaton told Ivanhoe.

Instead of surgery, where the chest is opened and stem cells are injected into the heart, Alan W. Helman, M.D., an interventional cardiologist at the University of Miami, delivers the cells through a catheter that’s threaded through the groin. The spiral-shaped needle at the tip is screwed into the heart.

“We can now inject the cells exactly where we want to in the inside part of the heart, and we can do it in multiple different locations,” Joshua Hare, M.D., a cardiologist at the University of Miami, told Ivanhoe.
Doctors say it’s a more efficient way of delivering stem cells (…) Now, Eaton is hoping his wager on stem cells will pay off.

Doctors say Eaton is responding well to his stem cell treatment. All of the stem cells being used in this trial are adult stem cells. Studies have shown injecting heart attack patients with adult stem cells can increase the pumping power of the heart. However, it is not an approved treatment for re-growing heart tissue.

Full-length interview with Dr. Hare

from http://ivanhoe.com/channels/p_channelstory.cfm?storyid=22514

Incoming search terms:

RIYADH – Stem Cells Unit at the Department of Anatomy in King Saud University will organize a conference on stem cell research and medical reconstruction at the Faculty of Medicine and King Khalid University Hospital on Nov. 7-9. First of its kind in the Kingdom, the conference will be held in cooperation with the KSU’s Center for Medical Education, the Australian National University and the University of South Denmark.
President of the Organizing Committee of the Conference, Dr. Abdullah Al-Dahmash, said here Saturday that the conference aims at presenting the latest developments in the field of stem cell research and therapeutic applications; to accentuate new technologies, research and applications of stem cells.

The aim is also to highlight the major advances in stem cell researches in the Kingdom in general, and King Saud University in particular and to increase awareness of the importance of stem cell researches.
The conference will address many topics including the role of stem cells in treating some diseases, especially those suffered by the Saudi society as well as modern techniques in stem cell researches (…)

from http://www.saudigazette.com.sa/index.cfm?method=home.regcon&contentID=2009101851903

Incoming search terms:

International Stem Cell Corporation, announces that it has launched fifteen new human cell culture products into the commercial research markets over the last twelve months through its wholly-owned subsidiary, Lifeline Cell Technology, (Walkersville, MD), leading to a 12-month average month-to-month revenue growth of 50%. ISCO, the parent company, is the first company to create human “parthenogenetic” stem cells from unfertilized eggs. Parthenogenetic stem cells not only solve ethical problems, but also promise to minimize immune-rejection by providing cells that can be immune-matched to large segments of the population.

These products represent milestone achievements in ISCO’s strategy of generating revenue from the sale of research products, while building infrastructure from that effort to expand the manufacturing and quality control capacities ISCO needs to commercialize the therapeutic applications of human parthenogenetic stem cells.

One of its newest and most promising products consist of “xeno-free” human cells and culture reagents that allow researchers to study embryonic stem cells without contamination from animal (non-human) components. These products meet the needs for stem cell research to be done using “human-only” systems. Other products include Lifeline’s living human cells and reagents for research and drug development into cardiovascular, kidney, lung, nerve, eye and skin disease. Lifeline is continuing to develop unique reagents and media for the growing field of stem cell research. The “Lifeline” brand of products consist of human cells and the culture reagents and growth factors needed to grow the cells.

According to Jeffrey Janus, CEO of Lifeline, “We are proud of the quality of our new products, as reflected in the sales growth they are exhibiting in the human cell research markets. We look forward to launching more new products into the growing markets for stem cell research and drug development. These products will contribute to the success of ISCO, not only by supporting ISCO’s therapeutic research, but also through the development of critical manufacturing and quality control systems necessary for ISCO to produce therapeutic human cells in the future.”

Lifeline’s products can be found at www.lifelinecelltech.com
For more news and information on International Stem Cell Corporation please visit www.IRGnews.com/coi/ISCO where you can find the CEO’s video, a fact sheet on the company, investor presentations, and more.

from http://www.internationalstemcell.com

Incoming search terms: